197 related articles for article (PubMed ID: 11180022)
1. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H
Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women.
Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Locher M; Derendorf H
J Clin Pharmacol; 2003 Mar; 43(3):243-51. PubMed ID: 12638392
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women.
Erb K; Klipping C; Duijkers I; Pechstein B; Schueler A; Hermann R
Fertil Steril; 2001 Feb; 75(2):316-23. PubMed ID: 11172833
[TBL] [Abstract][Full Text] [Related]
4. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers.
Pechstein B; Nagaraja NV; Hermann R; Romeis P; Locher M; Derendorf H
J Clin Pharmacol; 2000 Mar; 40(3):266-74. PubMed ID: 10709155
[TBL] [Abstract][Full Text] [Related]
6. Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics.
Erb K; Junge K; Pechstein B; Schneider E; Derendorf H; Hermann R
J Clin Pharmacol; 2002 Sep; 42(9):995-1001. PubMed ID: 12211225
[TBL] [Abstract][Full Text] [Related]
7. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.
Lee TH; Lin YH; Seow KM; Hwang JL; Tzeng CR; Yang YS
Fertil Steril; 2008 Jul; 90(1):113-20. PubMed ID: 18054932
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
[TBL] [Abstract][Full Text] [Related]
11. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
Behre HM; Kliesch S; Pühse G; Reissmann T; Nieschlag E
J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels.
Huirne JA; van Loenen AC; Schats R; McDonnell J; Hompes PG; Schoemaker J; Homburg R; Lambalk CB
Hum Reprod; 2004 Oct; 19(10):2206-15. PubMed ID: 15333605
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women.
Han S; Cho YS; Yoon SK; Lim KS; Cho SH; Kim J; Choe S; Jung J; Ghim JL; Choi S; Lee M; Kim SM; Kim HT; Lim HS; Yoon Shim J; Bae KS
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1111-e1120. PubMed ID: 33347565
[TBL] [Abstract][Full Text] [Related]
14. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers.
Duijkers IJ; Klipping C; Willemsen WN; Krone D; Schneider E; Niebch G; Hermann R
Hum Reprod; 1998 Sep; 13(9):2392-8. PubMed ID: 9806255
[TBL] [Abstract][Full Text] [Related]
15. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?
Chen HJ; Lin YH; Hsieh BC; Seow KM; Hwang JL; Tzeng CR
J Assist Reprod Genet; 2006 Jun; 23(6):289-92. PubMed ID: 16865530
[TBL] [Abstract][Full Text] [Related]
16. Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle.
Evans MJ; Alexander SL; Irvine CH; Kitson NE; Taylor TB
Anim Reprod Sci; 2011 Sep; 127(3-4):188-96. PubMed ID: 21889856
[TBL] [Abstract][Full Text] [Related]
17. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of an antagonist to gonadotrophin releasing hormone on the FSH and LH response to GnRH in perifused equine pituitary cells, and in seasonally acyclic mares.
Evans MJ; Kitson NE; Alexander SL; Irvine CH; Turner JE; Perkins NR; Livesey JH
Anim Reprod Sci; 2002 Sep; 73(1-2):37-51. PubMed ID: 12220817
[TBL] [Abstract][Full Text] [Related]
19. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.
Olivennes F; Fanchin R; Bouchard P; de Ziegler D; Taieb J; Selva J; Frydman R
Fertil Steril; 1994 Sep; 62(3):468-76. PubMed ID: 8062940
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
